Silicosis

1. Disease Information

Overview. Silicosis is a chronic, irreversible, fibrotic interstitial lung disease (a pneumoconiosis) caused by the inhalation of respirable crystalline silica (RCS, silicon dioxide, SiO₂). Inhaled silica particles are phagocytosed by alveolar macrophages, triggering a self-perpetuating cycle of macrophage death, inflammation, and progressive collagen deposition that produces the pathognomonic silicotic nodule and, in advanced disease, progressive massive fibrosis (PMF). It is one of the oldest recognized occupational diseases and is entirely preventable but incurable.

Key identifiers: - MONDO: MONDO:0005960 - ICD-10-CM: J62 (Pneumoconiosis due to dust containing silica); J62.8 (other silica-containing dust); J62.0 (talc) - ICD-11: CA60.0 (Silicosis) - MeSH: D012829 (Silicosis) - OMIM: Not applicable — no single-gene Mendelian entry; silicosis is not a Mendelian disorder - Orphanet: Not a rare disease per Orphanet (common occupational disease) - SNOMED CT: 40122008 (Silicosis)

Synonyms / alternative names: Miner's phthisis, grinder's asthma/disease, potter's rot, stonemason's disease, "the dust disease," pneumosilicosis, silicotic fibrosis. Subtype-linked terms: acute silicosis (acute silicoproteinosis/silicolipoproteinosis), accelerated silicosis, chronic (simple and complicated) silicosis, conglomerate silicosis (= PMF).

Data derivation. Information is drawn overwhelmingly from aggregated disease-level resources (occupational-disease registries, surveillance programs such as Australia's Queensland screening program and US state case series, and clinical/pathology literature) rather than single-patient EHR records. The engineered-stone outbreak literature draws on clinical case series and lung-transplant/autopsy cohorts.

2. Etiology

Disease causal factor (obligate environmental cause)

The sole necessary cause is inhalation of respirable crystalline silica — particles generally <5–10 µm aerodynamic diameter that reach the alveoli. Crystalline polymorphs, in order of typical toxicity relevance: - Quartz (most common) — CHEBI/chemical: silicon dioxide, SiO₂ - Cristobalite and tridymite — higher-temperature polymorphs, more fibrogenic; generated by heating/calcining quartz and abundant in engineered-stone processing - Freshly fractured silica (cutting, grinding, drilling) is more toxic than aged dust because fresh surfaces carry reactive silanol/radical groups.

Amorphous silica (e.g., diatomaceous earth in native form) is far less fibrogenic; calcination converts it to cristobalite, raising risk.

Risk factors — environmental / occupational (the dominant drivers)

• High-risk occupations: engineered/artificial "quartz" stone countertop fabrication (the current epidemic driver), hard-rock and coal mining, sandblasting (especially denim sandblasting), quarrying, tunneling, foundry work, ceramics/pottery, glass manufacture, stone masonry, construction (concrete cutting), dental laboratory work, hydraulic fracturing (sand proppant).
• Exposure intensity and duration determine clinical form: cumulative dose drives chronic disease; very high short-term exposure drives accelerated/acute forms.
• Engineered ("artificial") stone is the key modern factor: it contains >90% crystalline silica (vs ~30% in granite, <5% in marble), producing ultrafine (<1 µm) high-surface-area particles and dramatically shortening latency. Dry cutting without adequate wet suppression or respiratory protection is the proximate exposure.
• Cigarette smoking: additive/synergistic for functional decline, COPD, and markedly for lung cancer risk.
• Sex/age: predominantly male (occupational exposure pattern); engineered-stone cases occur in strikingly young men (median ~33–55 y), often immigrant/marginalized workers.

Risk factors — genetic (susceptibility/modifier only, not causal)

Genetic factors modulate who develops disease and how severely among the exposed; they are neither necessary nor sufficient: - TNF-α promoter polymorphisms (−308 G/A, −238 G/A): the −308A allele is associated with increased silicosis risk, especially in Asian populations; −238 promoter variants associated with severe silicosis in Black South African miners (PMID:11874815). Meta-analytic adjusted OR for −238 was reported very high (~20.9) in one cohort. - IL-1 receptor antagonist (IL-1RA / IL1RN) +2018 polymorphism: associated with susceptibility and severity (OR ~4.0). - Candidate-gene meta-analyses also implicate variants in IL-1β, IL-6, GSTM1/GSTT1/GSTP1 (glutathione-S-transferases), and HLA class II genes, with modest and population-dependent effects. No genome-wide-significant common causal locus is established.

Protective factors

• Environmental/engineering: wet cutting/dust suppression, local exhaust ventilation, enclosed automated processing, respiratory protection (powered air-purifying respirators), and regulatory exposure limits (US OSHA PEL 50 µg/m³ 8-h TWA for RCS; Australia's 2024 ban on engineered stone). These are the only proven protections.
• Genetic protective factors: none robustly established. Some anti-inflammatory cytokine alleles (e.g., high-IL-10 producers) have been hypothesized to be protective but are not confirmed.
• Behavioral: smoking cessation reduces downstream lung-cancer and COPD burden but does not prevent silicosis itself.

Gene–environment interaction

Silicosis is a paradigm of gene–environment interaction: an obligate environmental exposure whose fibrotic outcome is modulated by host inflammatory-gene polymorphisms (TNF-α, IL-1RA, GST detoxification genes). The interaction is quantitative (risk/severity modulation) rather than qualitative — no host genotype confers disease without silica exposure.

3. Phenotypes

Silicosis is often asymptomatic for years, especially in the simple chronic form. Phenotypes below are grouped by type with suggested HPO terms.

Respiratory symptoms/signs: - Dyspnea / exertional breathlessness — HP:0002094 (Dyspnea); the dominant symptom, progressive. Frequent, especially in complicated disease. - Chronic cough — HP:0031246 (Chronic cough) / HP:0012735 (Cough). Common, often productive. - Sputum production — HP:0033709 (Abnormal sputum) / HP:0031508. - Chest pain/tightness — HP:0100749 (Chest pain). - Wheezing — HP:0030828 (Wheezing). - Hemoptysis — HP:0002105 (Hemoptysis); should prompt evaluation for superimposed tuberculosis or PMF cavitation. - Cyanosis — HP:0000961 (Cyanosis); late/severe. - Bibasilar/diffuse crackles — HP:0030830 (Crackles); prominent in acute silicoproteinosis. - Digital clubbing — HP:0001217 (Clubbing); variable, less typical than in IPF.

Physical/systemic manifestations: - Fatigue — HP:0012378 (Fatigue). - Weight loss — HP:0001824 (Weight loss); acute/advanced disease. - Respiratory failure — HP:0002878 (Respiratory failure); end-stage. - Pulmonary hypertension / cor pulmonale — HP:0002092 (Pulmonary arterial hypertension); complication of advanced fibrosis. - Pneumothorax — HP:0002107 (Pneumothorax); complication.

Laboratory / imaging abnormalities: - Restrictive (± mixed obstructive) ventilatory defect — HP:0002091 (Restrictive ventilatory defect); reduced FVC, reduced DLCO on pulmonary function testing. - Pulmonary fibrosis — HP:0002206 (Pulmonary fibrosis). - Pulmonary nodules / reticulonodular opacities — HP:0031451 (Pulmonary nodule); upper/mid-lobe predominant small rounded opacities (ILO shapes q/r). - Hilar/mediastinal lymphadenopathy with "eggshell" calcification — HP:0100721 (Hilar lymphadenopathy); eggshell calcification is characteristic. - Elevated inflammatory/autoimmune serology — antinuclear antibodies, rheumatoid factor, ANCA may be positive (see Section 6/complications).

Phenotype characteristics by clinical form: | Form | Onset (latency) | Severity | Progression | Frequency | |---|---|---|---|---| | Chronic simple | 10–30+ y | Mild–moderate, often asymptomatic | Slow, may be stable | Most common historically | | Chronic complicated (PMF) | decades | Severe | Progressive (can progress after exposure ends) | ~subset of chronic | | Accelerated | 3–10 y | Moderate–severe | Rapid | Rising sharply (engineered stone) | | Acute (silicoproteinosis) | weeks–<5 y | Very severe | Rapid, often fatal | Rare, very high exposure |

Age of onset: adult; engineered-stone accelerated silicosis strikingly presents in the 3rd–5th decade. Progression: can continue after cessation of exposure, particularly complicated/PMF forms.

Quality-of-life impact. Advanced silicosis produces severe exertional limitation, oxygen dependence, inability to work (major socioeconomic impact given young affected workers), and psychological burden; PMF and lung-transplant candidacy indicate profound QoL reduction. No silicosis-specific validated instrument dominates; generic tools (SF-36, EQ-5D, St George's Respiratory Questionnaire) are used.

4. Genetic / Molecular Information

Not applicable as a Mendelian disorder. Silicosis has no causal gene, no pathogenic germline/somatic variant catalog, no ClinVar/HGMD pathogenic-variant set, and no chromosomal abnormality. It is not inherited.

What exists is susceptibility/modifier genetics (see Section 2): - Modifier/susceptibility genes: TNF (HGNC:11892; TNF-α −308/−238 promoter SNPs), IL1RN (IL-1 receptor antagonist, +2018), and candidate variants in IL1B, IL6, GSTM1/GSTT1/GSTP1, and HLA class II. Effects are small-to-moderate, population-specific, and function as risk/severity modifiers. - Variant classification: These are common-population regulatory polymorphisms, not ACMG "pathogenic" variants — the ACMG/AMP framework does not apply to a complex environmental trait. - Functional consequence: promoter variants alter cytokine expression levels (e.g., higher TNF-α transcription with −308A), amplifying the inflammatory/fibrotic response to silica.

Epigenetics: Silica exposure induces epigenetic reprogramming in lung cells and macrophages — DNA-methylation changes and dysregulated microRNAs are implicated in fibrogenesis (e.g., downregulation of miR-205-5p → ↑E2F1/SKP2 → impaired Beclin1-mediated autophagy; downregulation of miR-503 → ↑VEGFA/FGFR1 → ERK/MAPK activation). These are acquired, exposure-driven changes, not heritable disease mutations.

5. Environmental Information

• Environmental/occupational factor (causal): respirable crystalline silica dust — quartz, cristobalite, tridymite. Generated by mechanical disruption of silica-containing materials (see Section 2 occupations). Engineered stone is the dominant contemporary source.
• Chemical entity: silicon dioxide / crystalline silica (CHEBI: silicon dioxide, CHEBI:30563; quartz-specific and crystalline-SiO₂ terms also exist). IARC Group 1 human carcinogen (crystalline silica inhaled from occupational sources).
• Lifestyle factors: cigarette smoking (synergistic for lung cancer/COPD and functional decline). Diet/alcohol not established as major modifiers.
• Infectious agents: silica does not cause infection, but silicosis is a powerful risk multiplier for infection — notably Mycobacterium tuberculosis (NCBITaxon:1773) and nontuberculous mycobacteria; also increased susceptibility to community pneumonia and fungal infections. Silica impairs macrophage bactericidal function, explaining silicotuberculosis (see Sections 6 and 11).

6. Mechanism / Pathophysiology

Silicosis pathogenesis is a well-characterized causal cascade centered on the alveolar macrophage and the NLRP3 inflammasome.

Causal chain (upstream → downstream)

1. Deposition & recognition. Respirable silica (<5 µm) deposits in terminal bronchioles/alveoli. Alveolar macrophages (CL:0000583, alveolar macrophage) recognize and internalize particles via scavenger receptors, especially MARCO and SR-A, forming phagosomes. (GO:0006909 phagocytosis)
2. Lysosomal/phagolysosomal damage. Reactive silanol surface groups rupture the phagolysosomal membrane → lysosomal destabilization and leakage (cathepsin B release). (GO:0007042 lysosomal lumen acidification / membrane permeabilization)
3. Oxidative stress. Silica surface radicals and mitochondrial dysfunction generate reactive oxygen species (ROS). (GO:0006979 response to oxidative stress)
4. NLRP3 inflammasome assembly. Signal 1 (priming via TLR4/MyD88 → NF-κB) plus signal 2 (lysosomal rupture + ROS + extracellular ATP acting on the P2X7 receptor) drive NLRP3–ASC–caspase-1 assembly. (GO:0072559 NLRP3 inflammasome complex; GO:0002674 regulation of acute inflammatory response)
5. Cytokine maturation & macrophage death. Caspase-1 cleaves pro-IL-1β and pro-IL-18 → mature IL-1β / IL-18, and cleaves gasdermin D (GSDMD) → pyroptosis (inflammatory macrophage death). Released silica re-enters new macrophages, perpetuating the cycle. (GO:0070269 pyroptosis; GO:0050830 IL-1β secretion)
6. Inflammatory amplification / alveolitis. IL-1β, TNF-α, IL-6, IL-17A, and chemokines (CXCL1, CCL3/MIP-1α, CXCL2/MIP-2; CXCR4/CXCL12 axis) recruit neutrophils (CL:0000775) and monocytes; neutrophil extracellular traps recruit fibrocytes.
7. Epithelial injury & aberrant regeneration. Type II alveolar epithelial cells (CL:0002063, type II pneumocyte) are injured and undergo epithelial–mesenchymal transition (EMT). (GO:0001837 EMT)
8. Fibroblast/myofibroblast activation. TGF-β1 (master pro-fibrotic cytokine), PDGF, CTGF, and bFGF drive fibroblast → myofibroblast differentiation (CL:0000186, myofibroblast cell), with signaling through TGF-β/SMAD, CD44-RhoA-YAP, and 4-1BB pathways. (GO:0007179 TGF-β receptor signaling; GO:0060312 regulation of myofibroblast differentiation)
9. Excess ECM deposition & fibrosis. Myofibroblasts deposit type I/III collagen → the concentric, whorled hyalinized silicotic nodule; coalescence produces progressive massive fibrosis. (GO:0030198 extracellular matrix organization; GO:0072538 collagen fibril organization)
10. Architectural destruction → organ failure. Progressive fibrosis → restrictive physiology, ↓DLCO, pulmonary hypertension, respiratory failure.

Cellular processes

Phagocytosis, lysosomal membrane permeabilization, NLRP3 inflammasome activation, pyroptosis and apoptosis, ROS/oxidative stress, autophagy/mitophagy dysregulation, EMT, chronic inflammation, and fibrogenesis. ER stress in alveolar macrophages contributes to fibrogenesis (unfolded protein response).

Immune system involvement

Silica is a chronic immune adjuvant/immunotoxicant: it drives Th17/IL-17A responses, dysregulates regulatory T cells, and promotes autoantibody production, mechanistically linking silicosis to autoimmune disease (rheumatoid arthritis, systemic sclerosis, SLE, ANCA-associated vasculitis; Caplan syndrome = silicosis + seropositive RA with cavitating nodules). Silica-impaired macrophage function underlies the ~30-fold increased tuberculosis risk.

Molecular profiling

Transcriptomic and proteomic studies of silica-exposed lungs/macrophages show upregulation of inflammasome, TGF-β/SMAD, ECM, and EMT gene programs; single-cell and organotypic lung stem/progenitor models have demonstrated NLRP3-mediated epithelial injury and aberrant regeneration. RAGE (receptor for advanced glycation end-products) modulates the fibrotic response in murine silica models.

Therapeutic-target implications

NLRP3/caspase-1/IL-1β axis, P2X7 receptor, TGF-β signaling, ROS (antioxidants: N-acetylcysteine), and autophagy restoration are active preclinical/clinical targets (Section 12).

7. Anatomical Structures Affected

• Primary organ: lung (UBERON:0002048), especially upper and mid lung zones / posterior upper lobes (predilection site of silicotic nodules and PMF). Body system: respiratory system (UBERON:0001004).
• Secondary/associated involvement: hilar and mediastinal lymph nodes (UBERON:0000029) — "eggshell" calcification; pleura (UBERON:0000977) — pleural thickening; pulmonary vasculature / right heart — pulmonary hypertension and cor pulmonale (cardiovascular system, UBERON:0004535); systemic immune involvement (autoimmune sequelae).
• Tissue level: alveolar interstitium and parenchyma; bronchiolar walls; lymphoid tissue. Fibrotic remodeling of connective tissue.
• Cell populations targeted/involved (CL terms):
• Alveolar macrophage — CL:0000583
• Type II pneumocyte (alveolar epithelial type II) — CL:0002063
• Type I pneumocyte — CL:0002062
• Lung fibroblast — CL:0002553 / myofibroblast — CL:0000186
• Neutrophil — CL:0000775
• Fibrocyte / recruited monocyte-derived cells
• Subcellular compartments (GO Cellular Component): phagosome/phagolysosome and lysosome (GO:0005764), mitochondrion (GO:0005739, ROS source), endoplasmic reticulum (GO:0005783, ER stress), NLRP3 inflammasome complex (GO:0072559), extracellular matrix (GO:0031012).
• Localization/lateralization: bilateral, typically symmetric; upper-zone predominant. PMF masses often bilateral and may cavitate (raising TB suspicion).

8. Temporal Development

• Onset: adult-onset, occupationally determined. Latency is inversely proportional to exposure intensity:
• Chronic: ≥10 years (often 20–40) after low-moderate exposure.
• Accelerated: 3–10 years after high exposure (engineered stone).
• Acute (silicoproteinosis): weeks to <5 years after extreme exposure.
• Onset pattern: insidious (chronic) to subacute/acute (accelerated/acute forms).
• Stages/progression: simple silicosis (small opacities) → complicated silicosis/PMF (coalescent masses >1 cm). Progression can occur even after exposure ceases, particularly complicated disease. Acute silicoproteinosis progresses rapidly, often to fatal respiratory failure.
• Course: chronic, lifelong, generally irreversible and non-remitting; no spontaneous remission of established fibrosis. Critical "window": prevention is the only effective intervention — once fibrosis is established, disease-modifying options are limited to slowing progression.

9. Inheritance and Population

Epidemiology

• Global burden: Silicosis carries a high and, in some regions, rising global burden. The Global Burden of Disease Study 2021 provides incidence, mortality, and DALY estimates across 204 countries; pneumoconioses (silicosis, coal-workers', asbestosis) remain a substantial occupational-disease burden, with silicosis the largest single contributor in many analyses. Hundreds of thousands of prevalent cases worldwide; high burden in China, India, and other industrializing economies.
• Engineered-stone outbreak (contemporary epidemic):

• 1,000 engineered-stone silicosis cases identified worldwide since first reports ~2010 (Spain, Israel), then Australia and the US.

• United States (California): first cases 2019; 52 cases by 2023; 219 cases by November 2024, including ≥14 deaths and 26 lung transplantations — young, predominantly Latino immigrant male workers.
• Australia (Queensland screening, since 2018): of 1,054 stone-benchtop workers screened, 224 (21%) had silicosis and 36 (3.6%) had PMF (as of Aug 2024). Australia became the first country to ban engineered stone (July 2024).
• Prevalence/incidence: varies enormously by industry and region; no single "cases per 100,000" applies. Occupational cohorts (mining, stone benchtop) show double-digit prevalence percentages among the exposed.

Inheritance

• Not heritable. No Mendelian inheritance pattern, penetrance, expressivity, anticipation, mosaicism, founder effect, consanguinity role, or carrier frequency applies. Susceptibility is polygenic/multifactorial at most (Section 2 modifier genes) and always contingent on exposure.

Population demographics

• Sex: strongly male-predominant, reflecting occupational exposure distribution (male:female ratio high; engineered-stone cohorts are almost entirely male).
• Age: adults; engineered-stone accelerated cases cluster in young adults (median ~33–55 y).
• Ethnic/socioeconomic: disproportionately affects marginalized, immigrant, and low-income workers (US engineered-stone cases predominantly Latino immigrants). Geographic clustering follows mining/stone-processing industries and lax regulatory environments.
• Variant geography: not applicable (no disease-defining variants).

10. Diagnostics

Diagnosis rests on the triad: (1) exposure history, (2) characteristic imaging, (3) exclusion of alternatives — biopsy is usually unnecessary.

Imaging (cornerstone): - Chest radiograph classified by the ILO International Classification of Radiographs of Pneumoconioses — small rounded opacities (profusion, shapes typically q/r), upper-zone predominance; large opacities (A/B/C) define complicated disease/PMF; "eggshell" calcification of hilar nodes. - HRCT (higher sensitivity/specificity than CXR): centrilobular and subpleural micronodules, upper/mid-lobe predominance, conglomerate masses (PMF, often with surrounding emphysema and calcification), lymphadenopathy. RadLex/DICOM-coded.

Functional tests: - Spirometry/full PFTs: restrictive, mixed, or (with smoking) obstructive pattern; reduced DLCO; reduced 6-minute walk distance / desaturation in advanced disease.

Laboratory / biomarkers: - No validated diagnostic serum biomarker in routine use; research candidates include serum SP-D, KL-6/MUC1, CC16, and inflammatory cytokines. - Autoimmune serologies (ANA, RF, ANCA) when overlap syndromes suspected. - Tuberculosis screening is mandatory (IGRA/tuberculin, sputum studies) given silicotuberculosis risk.

Histopathology (when biopsy performed): whorled, concentric hyalinized collagen silicotic nodules with birefringent particles under polarized light; acute form shows alveolar filling with PAS-positive lipoproteinaceous material (silicoproteinosis, resembling alveolar proteinosis). Mineralogical analysis (SEM-EDX) can confirm silica.

Genetic testing: Not applicable for diagnosis (no causal gene). WGS/WES/panels/karyotype/FISH/CMA have no diagnostic role. Genotyping for susceptibility SNPs is research-only.

Clinical criteria / differential diagnosis. No DSM/formal consensus "criteria set" beyond exposure + imaging pattern; occupational-medicine society guidance (ATS, ACOEM, ILO) applies. Differential: coal-workers' pneumoconiosis, sarcoidosis (both can give upper-zone nodules and hilar adenopathy), tuberculosis, metastatic pulmonary calcification, hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, berylliosis, pulmonary Langerhans cell histiocytosis. Exposure history and mineralogy distinguish silicosis.

Screening. Occupational surveillance of exposed workers (periodic ILO-classified CXR/HRCT + spirometry + TB screening), as in the Queensland engineered-stone program — a secondary-prevention model. No newborn/carrier/genetic screening (non-genetic disease).

11. Outcome / Prognosis

• No cure. Prognosis depends on form, radiographic category, and progression to PMF. Simple chronic silicosis may remain stable and compatible with near-normal lifespan; complicated silicosis/PMF, accelerated, and acute forms carry poor prognosis.
• Acute silicoproteinosis: frequently fatal within months–few years.
• Accelerated/engineered-stone silicosis: poor — high rates of progression to PMF, respiratory failure, lung transplantation, and death in young patients; US cohort documented ≥14 deaths and 26 transplants among 219 cases.
• Mortality: disease-specific mortality from respiratory failure and cor pulmonale; excess mortality from tuberculosis, lung cancer, and COPD.
• Complications (major):
• Tuberculosis (silicotuberculosis): ~30× increased risk in silicosis (and ~3× in silica-exposed without silicosis); NTM infections also increased.
• Lung cancer: crystalline silica is an IARC Group 1 carcinogen; increased lung-cancer risk, synergistic with smoking.
• Autoimmune/connective-tissue disease: rheumatoid arthritis (incl. Caplan syndrome), systemic sclerosis/scleroderma, SLE, ANCA-associated vasculitis and glomerulonephritis; chronic kidney disease (silica nephrotoxicity/vasculitis).
• COPD/emphysema, chronic bronchitis, airflow obstruction.
• Pulmonary hypertension and cor pulmonale; pneumothorax; recurrent respiratory infections; respiratory failure.
• Morbidity/QoL: progressive disability, oxygen dependence, loss of employment; heavy socioeconomic impact given young working-age patients.
• Prognostic factors: exposure intensity/duration, radiographic profusion and presence/extent of PMF, rate of radiographic progression, DLCO/FVC decline, superimposed TB or malignancy, and continued exposure.

12. Treatment

No disease-reversing therapy exists; management is supportive, complication-directed, and increasingly antifibrotic-experimental. Suggested MAXO terms noted.

Foundational / supportive care (MAXO:0000950 supportive care): - Exposure cessation (remove worker from silica) — essential first step. - Smoking cessation (MAXO behavioral/counseling terms). - Oxygen therapy for hypoxemia (MAXO:0035008 oxygen therapy / supplemental oxygen). - Pulmonary rehabilitation (MAXO:0000915 rehabilitation / physiotherapy). - Vaccination — influenza, pneumococcal (± SARS-CoV-2) to reduce respiratory infections (MAXO:0001017 vaccination). - Prompt treatment of respiratory infections.

TB prevention/treatment: - Screening and treatment of latent/active tuberculosis with standard antimycobacterial regimens (isoniazid, rifampicin, etc.) — critical given silicotuberculosis risk (MAXO:0000058 pharmacotherapy / antibiotic therapy).

Pharmacotherapy (limited evidence): - Corticosteroids — may modestly reduce inflammation/alveolitis in some accelerated/acute cases; not disease-modifying for established fibrosis. - Antifibrotics — pirfenidone and nintedanib: approved for IPF, showing benefit in silicosis animal models and small clinical studies (reducing inflammation/fibrosis, pulmonary hypertension in early disease); under active clinical investigation (e.g., NCT05118256, pirfenidone in complicated silicosis). Not yet standard-of-care/approved for silicosis. - N-acetylcysteine (antioxidant) — protective in murine silicosis models; adjunctive human use investigational. - Investigational/preclinical targeted agents: NLRP3 inflammasome inhibitors, IL-1 blockade, P2X7 antagonists, TGF-β pathway inhibitors, metformin, trehalose (autophagy inducers), and nanoparticle-targeted pulmonary delivery.

Procedural: - Whole-lung lavage (WLL) — reduces dust/inflammatory burden; most useful in early and accelerated silicosis and acute silicoproteinosis; use cautiously in advanced disease (MAXO — therapeutic bronchopulmonary lavage / therapeutic procedure). - Lung transplantation — the only definitive option for end-stage PMF/respiratory failure; increasingly performed in young engineered-stone patients (MAXO:0010039 organ transplantation).

Pharmacogenomics: Not applicable (no genotype-guided silicosis drug therapy established).

Treatment strategy: stage-based — remove exposure + supportive care + TB/infection and complication management for all; antifibrotic trials/WLL for progressive early disease; transplantation for end-stage. Personalized/precision approaches are investigational.

13. Prevention

Prevention is the only truly effective intervention — silicosis is 100% preventable.

• Primary prevention (eliminate/reduce exposure):
• Substitution/bans: Australia's engineered-stone ban (July 2024); substituting low-silica materials.
• Engineering controls: wet cutting/water suppression, local exhaust ventilation, enclosed/automated processing, dust containment.
• Administrative controls & PPE: enforced exposure limits (OSHA RCS PEL 50 µg/m³), respiratory protection (fit-tested respirators/PAPRs), worker training, hygiene.
• Regulatory enforcement and worker education, especially targeting small stone-fabrication shops and immigrant workforces.
• Secondary prevention (early detection): occupational medical surveillance — periodic ILO-classified chest imaging, spirometry, and TB screening of exposed workers (Queensland program model); removal from exposure at earliest signs.
• Tertiary prevention (limit complications): TB chemoprophylaxis/treatment, vaccination, smoking cessation, pulmonary rehab, treatment of comorbidities, and lung-cancer vigilance.
• Public-health interventions: dust-control legislation, industry licensing, hazard communication, and international efforts (WHO/ILO Global Programme for the Elimination of Silicosis, targeting elimination).
• Immunization: no vaccine against silicosis; respiratory-pathogen vaccines reduce complication burden.
• Genetic counseling / screening: not applicable (non-genetic disease).

14. Other Species / Natural Disease

• Taxonomy: Silicosis-like pneumoconiosis can be induced experimentally in mammals; naturally occurring silica pneumoconiosis is reported in horses (Equus caballus, NCBITaxon:9796) — e.g., California ranch horses exposed to silica-rich (cristobalite) soil dust develop a silicate-associated pneumoconiosis and osteoporosis syndrome. Grazing livestock and possibly other animals in silica-dusty environments may be affected.
• Veterinary relevance: limited but documented (equine silicosis/silicate pneumoconiosis with bone fragility); primarily an environmental veterinary concern rather than a genetic one.
• Comparative biology: the macrophage–inflammasome–fibrosis mechanism is evolutionarily conserved across mammals, which is why rodent models faithfully reproduce nodular fibrosis. NLRP3 inflammasome biology is conserved.
• Zoonosis/transmission: none — silicosis is non-infectious and non-transmissible; it is an exposure disease with no cross-species transmission.

15. Model Organisms

Silicosis is modeled by inducing silica exposure (not genetic engineering), making animal models highly relevant.

• Predominant model — mouse (Mus musculus, NCBITaxon:10090):
• Strain: C57BL/6(J) is the standard "high-responder," most susceptible to silica- and bleomycin-induced fibrosis (vs resistant strains such as CBA/J).
• Induction routes: oropharyngeal aspiration of crystalline silica suspension (produces a superior, more reproducible silicosis model than intratracheal instillation), intratracheal/intranasal instillation, and repeated inhalation/nose-only exposure (a model built by repeated nasal silica inhalation better mimics chronic human exposure). Silica delivery produces fibrotic nodules resembling human silicotic lesions.
• Rat models: used for inhalation and instillation studies of silica fibrosis and for antifibrotic drug testing.
• Comparison with bleomycin model: the bleomycin model is the classic pulmonary-fibrosis model but is typically self-limited/resolving; the silica model produces persistent, progressive nodular fibrosis more faithful to human silicosis chronicity. Mechanistic divergences exist (e.g., RAGE knockouts are protected in bleomycin but not asbestos/silica-type fibrosis).
• In vitro / cellular models: primary and immortalized alveolar macrophages (e.g., MH-S), THP-1 monocyte-derived macrophages, type II epithelial lines (A549, MLE-12), and fibroblast lines exposed to crystalline silica to dissect NLRP3 activation, pyroptosis, and EMT/fibroblast activation. Lung stem/progenitor-cell-derived organotypic (organoid) models have demonstrated NLRP3-mediated epithelial injury and aberrant regeneration.
• Genetic models used as tools: knockouts of Nlrp3, Casp1, Il1b, Il1r1, P2rx7, Tnf, Ager (RAGE), and Marco on silica-exposed backgrounds dissect pathway contributions (e.g., NLRP3 deficiency abrogates silica-induced neutrophil infiltration, damage, and fibrosis).
• Phenotype recapitulation: rodent silica models reproduce alveolar macrophage activation/pyroptosis, granulomatous silicotic nodules, neutrophilic alveolitis, TGF-β-driven collagen deposition, and restrictive physiology — strong fidelity. Limitations: rodents do not fully reproduce human PMF conglomerate masses, the decades-long chronicity, silicotuberculosis (rodents handle M. tuberculosis differently), or the human autoimmune spectrum. Particle dose/delivery is non-physiologic (bolus vs chronic aerosol).
• Model resources: MGI, IMPC/KOMP (for knockout alleles of pathway genes), and published silica-exposure protocols (JoVE, methods papers).

Evidence Source Classification Summary

• HUMAN_CLINICAL: epidemiology (GBD 2021, engineered-stone case series in US/Australia/Spain/Israel), clinical forms, complications (silicotuberculosis, autoimmune associations), genetic-susceptibility case-control/meta-analyses, treatment/WLL/transplant series.
• MODEL_ORGANISM: murine/rat silica-instillation and knockout studies; equine natural disease; N-acetylcysteine and RAGE studies.
• IN_VITRO: macrophage/epithelial/fibroblast silica-exposure studies, organotypic lung-progenitor models.
• COMPUTATIONAL: network-pharmacology/molecular-docking studies of pirfenidone in silicosis.

Key Sources / Citations

Verified identifiers should be confirmed against the local MONDO/HP/CL/GO adapters before entry (per the dismech anti-hallucination SOP). Suggested key references for curation (verify PMIDs and quote exact abstract substrings with just fetch-reference before use):

• Sherekar et al., "Global scenario of silica-associated diseases: emerging pathophysiology of silicosis and potential therapeutic regimes," Toxicology Reports, 2025 — PMC11847043 (comprehensive mechanism review).
• "The role of inflammation in silicosis," Frontiers in Pharmacology, 2024 — 10.3389/fphar.2024.1362509.
• "NLRP3 deficiency abrogates silica-induced neutrophil infiltration, pulmonary damage and fibrosis" — PMC11929224.
• "A review of silicosis and other silica-related diseases in the engineered stone countertop processing industry," J Occup Med Toxicol, 2025 — PMC11917111.
• "Deadly Countertops: An Urgent Need to Eliminate Silicosis among Engineered Stone Workers," 2025 — PMC12005022.
• "Burden of silicosis based on the Global Burden of Disease Study 2021…" — PMC11898348.
• "Global burden of pneumoconiosis from 1990 to 2021…" — PMC12055836.
• Corbett et al., TNF-α promoter polymorphisms and severe silicosis in Black South African miners — PMID:11874815.
• "Candidate gene polymorphisms associated with silicosis and coal workers' pneumoconiosis: systematic review/meta-analysis" — PMC11585218.
• "TNF-α 308G/A polymorphism and silicosis susceptibility: a meta-analysis," PLoS One — PMC3790741.
• "From Basic Research to Clinical Practice: Considerations for Treatment Drugs for Silicosis" — PMC10179659.
• Pirfenidone in complicated silicosis trial — NCT05118256.
• "N-acetylcysteine therapeutically protects against pulmonary fibrosis in a mouse model of silicosis" — PMC6639458.
• "The Role of RAGE in a Murine Model of Silicosis" — PMC2841632.
• Silicosis overview — Merck Manual Professional; Wikipedia.
• Silicotuberculosis — PMC (silicotuberculosis outbreak, LA County); Caplan syndrome — PMC8136599.
• ER stress in alveolar macrophages / silicosis fibrosis — PMC10734631.
• NLRP3 in lung stem/progenitor organotypic models — IJBS v19p1875.

Curation caveat (dismech SOP): Two references are already cached in this branch (PMID_18577586, PMID_18604214) — verify their content and snippets before citing. Every PMID, ontology term (MONDO:0005960, HP/CL/GO/CHEBI IDs suggested above), and snippet in this report must be independently verified with just fetch-reference and just validate-terms-file before entering the KB, per the anti-hallucination workflow. The GBD-derived numeric burden figures and engineered-stone case counts should be pinned to the specific source table and quoted exactly.

Sources (web): - PMC11847043 — Global scenario of silica-associated diseases - Frontiers Pharmacology 2024 — Role of inflammation in silicosis - PMC11917111 — Engineered stone silicosis review - PMC12005022 — Deadly Countertops - PMC11898348 — GBD 2021 silicosis burden - PMC12055836 — GBD pneumoconiosis 1990–2021 - PMID:11874815 — TNF-α polymorphisms, South African miners - PMC11585218 — Candidate gene polymorphism meta-analysis - PMC10179659 — Treatment drugs for silicosis - NCT05118256 — Pirfenidone in complicated silicosis - Merck Manual — Silicosis - Wikipedia — Silicosis - MalaCards — Silicosis (identifiers) - ICD-10 J62